Adamas Pharmaceuticals, Inc (ADMS)

Etorro trading 970x250
Adamas Pharmaceuticals, Inc (ADMS) Logo

About Adamas Pharmaceuticals, Inc

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer’s type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Address: 1900 Powell Street, EmeryVille, CA, United States, 94608

Adamas Pharmaceuticals, Inc News and around…

Latest news about Adamas Pharmaceuticals, Inc (ADMS) common stock and company :

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021
17 Nov, 2021 FinancialContent

Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:ONON) was changed from Sell to Hold. ...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm
22 Oct, 2021 FinancialContent
Why Supernus' Acquisition of Adamas Is a Smart Move
21 Oct, 2021 FinancialContent

Adamas looks like a good fit for Supernus.

ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. -
12 Oct, 2021 FinancialContent

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, shareholders of Adamas will receive only $8.10 in cash and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (assuming certain conditions are met) for each share of Adamas that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

ADMS Crosses Above Average Analyst Target
12 Oct, 2021 FinancialContent

In recent trading, shares of Adamas Pharmaceuticals Inc (ADMS) have crossed above the average analyst 12-month target price of $7.92, changing hands for $8.07/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
12 Oct, 2021 FinancialContent

Upgrades For Callaway Golf Co (NYSE:ELY), Compass Point upgraded the previous rating of Neutral to Buy. Callaway Golf earned $0.36 in ...

46 Biggest Movers From Yesterday
12 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full ...

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
11 Oct, 2021 FinancialContent

Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened in the markets thus far.

12 Health Care Stocks Moving In Monday's Intraday Session
11 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. ...

Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
11 Oct, 2021 FinancialContent

Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, ...

28 Stocks Moving In Monday's Mid-Day Session
11 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on ...

ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News
11 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. The post ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADMS
11 Oct, 2021 FinancialContent

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash is fair to Adamas shareholders.

Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights
11 Oct, 2021 FinancialContent

Supernus Pharmaceuticals Inc(NASDAQ: SUPN)has agreed to acquireAdamas Pharmaceuticals Inc(NASDAQ: ADMS) for ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
11 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We're kicking off the week right with a look at the biggest pre-market stock market movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Adamas Announces New Employment Inducement Grants
08 Oct, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Implied IEIH Analyst Target Price: $43
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards
01 Oct, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UCSF Health Awards 2021 New Therapeutics category. This year’s UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories. Companies selected as finalists have been evaluated on innovation, impact, and value of their product to improve patient outcomes. Adamas’ new therapeutic is GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease.

Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress
16 Sep, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 – 22, 2021. The poster presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes.

Looking Into Adamas Pharmaceuticals's Return On Capital Employed
10 Sep, 2021 FinancialContent

According to data from Benzinga Pro, during Q2, Adamas Pharmaceuticals's (NASDAQ:ADMS) reported sales totaled $21.97 million. Despite a ...

Adamas to Present at Upcoming September Investor Conferences
30 Aug, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will present at the following virtual investor conferences during the month of September 2021:

Adamas Announces New Employment Inducement Grant
13 Aug, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Adamas Pharmaceuticals Inc (ADMS) Q2 2021 Earnings Call Transcript
10 Aug, 2021 FinancialContent

ADMS earnings call for the period ending June 30, 2021.

Adamas Reports Second Quarter 2021 Financial Results
09 Aug, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2021, and recent corporate highlights.

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021
02 Aug, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101
22 Jul, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announces the issuance of two patents covering GOCOVRI® (amantadine) extended-release capsules: U.S. Patent No. 11,065,213 issued on July 20, 2021, and U.S. Patent No. 11,077,073, projected to issue on August 3, 2021. These two patents are the first issued in this patent family and provide additional claims covering the drug product GOCOVRI, the company’s medicine approved as the first and only drug to treat both dyskinesia and OFF motor complications in Parkinson’s patients, and methods of using GOCOVRI.

Adamas to Present at Upcoming William Blair Biotech Focus Conference
08 Jul, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 1:00 pm Eastern Time.

Adamas to Present at Upcoming SVB Leerink CNS Forum
23 Jun, 2021 FinancialContent

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present “What’s Happening in Parkinson’s Disease & the GOCOVRI Opportunity” at the SVB Leerink CNS Forum on Tuesday, June 29th at 1:10 pm Eastern Time.

Adamas Pharmaceuticals, Inc (ADMS) is a NASDAQ Common Stock listed in , ,

970x250